Key result
Doxorubicin-BSA-dextran nanoparticles significantly prolonged the life of murine ascites hepatoma H22 tumor-bearing mice.
Why the study?
Do doxorubicin-BSA-dextran nanoparticles prolong the life of murine ascites hepatoma H22 tumor-bearing mice?
Do doxorubicin-BSA-dextran nanoparticles prolong the life of murine ascites hepatoma H22 tumor-bearing mice?
Doxorubicin-BSA-dextran nanoparticles prepared via a green process demonstrate significant antitumor efficacy by prolonging survival in a murine hepatoma model.
Extends preclinical support for doxorubicin nanoparticles in hepatoma models; leaves open human translation.
In this report, we developed a simple and green process of simultaneous formation of doxorubicin-BSA-dextran nanoparticles in aqueous solution and high-effective encapsulation of doxorubicin. In the presence of BSA-dextran conjugates, which were produced by Maillard reaction, a binding of doxorubicin with BSA can suppress the self-aggregation of unprotonated doxorubicin. After a heat treatment, the gelation of BSA results in a formation of the nanoparticles and the doxorubicin was fixed inside the nanoparticles. The dextran shell makes the nanoparticles dispersible in solution. The nanoparticles have a spherical morphology and a hydrodynamic radius of about 90 nm. Importantly, the nanoparticles can significantly prolong the life of murine ascites hepatoma H22 tumor-bearing mice.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2010) studied Murine ascites hepatoma H22. Doxorubicin-BSA-dextran nanoparticles was evaluated on Survival (prolonging life). Doxorubicin-BSA-dextran nanoparticles significantly prolonged the life of murine ascites hepatoma H22 tumor-bearing mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: